Peptide Therapeutics intermediate
Milestone 012: Oligopeptide Research Reference
2011: First GLP-1 agonist for obesity (liraglutide/Saxenda) approved. Revolutionizes obesity treatment. This peptide or oligopeptide is studied for its biolo...
By Encyclopeptide Editorial | 1 min read
milestone-012 peptide research
Overview
2011: First GLP-1 agonist for obesity (liraglutide/Saxenda) approved. Revolutionizes obesity treatment.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “Milestone 012” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Milestone 012: Oligopeptide Research Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept